Full history for every metric is available with a Kvantra account
Concert Pharmaceuticals, Inc. (CNCE)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 144 | 11 | 1 | 8 | 33 |
| Operating profit | $m | -78 | |||||
| Net profit | $m | -51 | 96 | -56 | -77 | -75 | -83 |
| EPS reported | $ | -2.40 | |||||
| Operating cashflow per share | $ | -1.60 | |||||
| Capex per share | $ | 0.01 | |||||
| FCF per share | $ | -1.61 | |||||
| Free cash flow | $m | -55 | |||||
| Net debt | $m | -128 | |||||
| Book value equity | $m | 112 | |||||
| Book value per share | $ | 3.26 | |||||
| Number of shares | m | 34.41 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 0.97 | |||||
| P/S LTM | x | 3.33 | |||||
| P/FCF LTM | x | -1.96 | |||||
| EV/EBITDA LTM | x | 0.25 | |||||
| EV/Sales LTM | x | -0.56 | |||||
| Earnings Yield LTM | % | -76.21% | |||||
| FCF Yield | % | -51.13% | |||||
| Quality | |||||||
| ROE | % | -73.60% | |||||
| ROIC | % | -51.55% | |||||
| Operating margin | % | -237.92% | |||||
| Gross margin | % | 100.00% | |||||
| FCF/Sales | % | -170.08% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +312.28% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -3.68 | |||||
| Net Debt/EBITDA | x | 1.72 | |||||
| EBIT/Net interest | x | 0.00 | |||||
| Net debt/market cap | % | -118.14% | |||||
| Net debt/Equity | x | -1.14 | |||||
| Gross debt/equity | x | 0.13 | |||||
Company overview
Concert Pharmaceuticals, Inc. functions as a biopharmaceutical firm in the clinical development phase, concentrating on the creation of innovative small-molecule therapeutics designed to address autoimmune conditions. Its primary investigational drug, CTP-543, is currently progressing through late-stage (Phase III) clinical trials for the treatment of alopecia areata, a serious autoimmune dermatological ailment. The company maintains strategic alliances with several partners, including Avanir Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Cipla Technologies, and Processa Pharmaceuticals. Established in 2006, the organization's corporate headquarters are situated in Lexington, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Concert Pharmaceuticals, Inc. (CNCE)
Concert Pharmaceuticals, Inc. functions as a biopharmaceutical firm in the clinical development phase, concentrating on the creation of innovative small-molecule therapeutics designed to address autoimmune conditions. Its primary investigational drug, CTP-543, is currently progressing through late-stage (Phase III) clinical trials for the treatment of alopecia areata, a serious autoimmune dermatological ailment. The company maintains strategic alliances with several partners, including Avanir Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Cipla Technologies, and Processa Pharmaceuticals. Established in 2006, the organization's corporate headquarters are situated in Lexington, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free